Last reviewed · How we verify
mRNA-3705
At a glance
| Generic name | mRNA-3705 |
|---|---|
| Also known as | modified mRNA encoding human, methylmalonyl-coenzyme A mutase |
| Sponsor | ModernaTX, Inc. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of mRNA-3705 in Participants With Isolated Methylmalonic Acidemia (PHASE1, PHASE2)
- An Extension Study to Evaluate the Long-Term Safety and Clinical Activity of mRNA-3705 in Participants Previously Enrolled in Other Clinical Studies of mRNA-3705 (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- mRNA-3705 CI brief — competitive landscape report
- mRNA-3705 updates RSS · CI watch RSS
- ModernaTX, Inc. portfolio CI